Раздел 5.6. Саркома Юинга

1. De Vita V., Hellmann S., Rosenberg S. Cancer: Principles and Practice of Oncology. 6th Edition. Lippincott Williams & Wilkins, 2001.
2. Windfuhr J.P. Primitive neuroectodermal tumor of the head and neck: incidence, diagnosis, and management // Ann. Otol. Rhinol. Laringol. 2004. Vol. 113, N 7. P. 533–543.
3. Ewing J. Diffuse endothelioma of bone Proc // N.-Y.Path. Soc. 1921. Vol. 21. P. 17.
4. De Alava et al. Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family // J. Clin. Oncol. 2000. Vol. 18. P. 204–213.
5. Pierron G., Tirode F., Lucchesi C. et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion // Nat. Genet. 2012. Vol. 44, N 4. P. 461–466.
6. Jenkin R.D. Ewing’s sarcoma a study of treatment methods // Clin. Radiol. 1966. Vol. 17. P. 97–106.
7. Дурнов Л.А., Голдобенко Г.В. Детская онкология: Учебник. 2-е изд., перераб. и доп. М.: Медицина, 2002. C. 385.
8. Нейштадт Э.Л., Маркочев А.Б. Опухоли и опухолеподобные заболевания костей. СПб.: Фолиант, 2007. С. 51–89.
9. Enneking W.F., Dunham W.K. Resection and reconstruction for primary neoplasms involving the innominate bone // J. Bone Joint. Surg. Am. 1978. Vol. 60. P. 731–746.
10. Wagner M.J., Gopalakrishnan V., Ravi V. et al. Vincristine, ifosfamide, and doxorubicin for initial treatment of Ewing sarcoma in adults // Oncologist. 2017. Vol. 22, N 10. P. 1271–1277. DOI: 10.1634/theoncologist.20160464.
11. Important Recently Characterized Non-Ewing Small Round Cell Tumors // Surg. Pathol. Clin. 2019. Vol. 12, N 1. P. 191–215. DOI: 10.1016/j.path.2018.10.008.
12. Peters T.L., Kumar V., Polikepahad S. et al. BCORCCNB3 fusions are frequent in undifferentiated sarcomas of male children // Mod. Pathol. 2015. Vol. 28, N 4. P. 575–586.
13. Самбурова Н.В., Пименов И.А., Жевак Т.Н., Литвицкий П.Ф. Саркома Юинга: молекулярно-генетические механизмы патогенеза // Вопросы современной педиатрии. 2019. Vol. 18, N 4. P. 257–263. DOI: 10.15690/ vsP.v18i4.2042.
14. Leavey P.J., Mascarenhas L., Marina N. et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology Group // Pediatr. Blood. Cancer. 2008. Vol. 51, N 3. P. 334–338. DOI: 10.1002/pbc.21618.
15. Esiashvili N., Goodman M., Marcus R.B. Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data // J. Pediatr. Hematol. Oncol. 2008. 30, N 6. P. 425–430.
16. Shankar A.G., Ashley S., Craft A.W., Pinkerton C.R. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma // Med. Pediatr. Oncol. 2003. Vol. 40, N 3. P. 141–147. DOI: 10.1002/mpo.10248.
17. Ferrari S., Luksch R., Hall K.S. et al. Post-relapse survival in patients with Ewing sarcoma // Pediatr. Blood. Cancer. 2015. Vol. 62, N 6. P. 994–999. DOI: 10.1002/ pbc.25388.